Bio-Rad Laboratories Inc. (BIO)

287.93
1.13 0.39
NYSE : Health Technology
Prev Close 289.06
Open 288.68
Day Low/High 285.00 / 289.03
52 Wk Low/High 208.95 / 297.59
Volume 126.14K
Avg Volume 157.40K
Exchange NYSE
Shares Outstanding 24.70M
Market Cap 8.72B
EPS 4.10
P/E Ratio 11.36
Div & Yield N.A. (N.A)

Latest News

Bio-Rad To Present At Barclays Global Healthcare Conference 2018 On March 14

Bio-Rad To Present At Barclays Global Healthcare Conference 2018 On March 14

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, and Christine Tsingos, Executive Vice...

Bio-Rad Reports Fourth-Quarter And Full-Year 2017 Financial Results

Bio-Rad Reports Fourth-Quarter And Full-Year 2017 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2017.

Bio-Rad To Report Fourth-Quarter And Full-Year 2017 Financial Results Tuesday, February 27, 2018

Bio-Rad To Report Fourth-Quarter And Full-Year 2017 Financial Results Tuesday, February 27, 2018

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2017 on Tuesday, February 27,...

Bio-Rad Gains Additional U.S. FDA Clearances For Blood Typing Products, Expanding Its Offering For The Blood Testing Market

Bio-Rad Gains Additional U.S. FDA Clearances For Blood Typing Products, Expanding Its Offering For The Blood Testing Market

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received 510(k) clearance from the U.

Bio-Rad Authorizes New $250 Million Share Repurchase Program

Bio-Rad Authorizes New $250 Million Share Repurchase Program

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced that its board of directors has authorized a new share repurchase program,...

Bio-Rad To Webcast Investor Day 2017

Bio-Rad To Webcast Investor Day 2017

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced that it will webcast Bio-Rad Investor Day 2017 on November 28.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BIO, BURL, DHT, GSAT, LGIH, NAP, ORA, PENN, VJET, XNET Downgrades: ARCC, BHE, FLWS, GPS, JOBS, MNRO, RGEN, TRGP, ZAYO Initiations: ACIU, AZRE, DTV Read on to get TheStreet Quant Ratings' detailed report:

Bio-Rad Reports Third-Quarter 2017 Financial Results

Bio-Rad Reports Third-Quarter 2017 Financial Results

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2017.

Bio-Rad To Report Third-Quarter 2017 Financial Results Thursday, November 2, 2017

Bio-Rad To Report Third-Quarter 2017 Financial Results Thursday, November 2, 2017

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2017 on Thursday, November 2, 2017, following...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AEL, CNMD, DATA, IAC, KBR, KHC, KOP, NPO, PBR.A, REG, SHAK, SQ, STOR, WMS, XPO Downgrades: ABC, AXTA, BIO, BIO.B, CNSL, DISH, GNE, HL, MCS, TGP, TNK, WEYS, WRLD Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Stocks Mixed Again as Dow Declines but Nasdaq Remains on Track for Record Close

Stocks Mixed Again as Dow Declines but Nasdaq Remains on Track for Record Close

Stocks turn mixed on Tuesday, though the Nasdaq remains on track to set to record a close for its third day in a row.

Stocks Turn Positive, Nasdaq Trades Above Record Closing High

Stocks Turn Positive, Nasdaq Trades Above Record Closing High

Stocks turn higher Tuesday as crude oil declines and the fourth-quarter earnings season draws closer.

Biotech Premarket Movers: ILMN, NSTG, KITE

Biotech Premarket Movers: ILMN, NSTG, KITE

Illumina, NanoString Technologies and Kite Pharma are among the premarket movers in biotech.

Microbiome MDx Specialist Genetic Analysis And Bio-Rad Sign Agreement

Microbiome MDx Specialist Genetic Analysis And Bio-Rad Sign Agreement

Genetic Analysis (GA) and Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, today announced that they have signed an agreement in which Genetic Analysis will receive...

Illumina And FlowJo, LLC Partner To Develop And Co-Market A Software Solution For Single Cell Genomics

Illumina And FlowJo, LLC Partner To Develop And Co-Market A Software Solution For Single Cell Genomics

Illumina, Inc. (NASDAQ: ILMN) and FlowJo, LLC, today announced a partnership to develop and co-market analysis software for single cell next-generation sequencing (NGS) data.

Bio-Rad Laboratories (BIO) Hits New Lifetime High Today

Bio-Rad Laboratories (BIO) Hits New Lifetime High Today

Trade-Ideas LLC identified Bio-Rad Laboratories (BIO) as a new lifetime high candidate

Strong And Under The Radar: Bio-Rad Laboratories (BIO)

Strong And Under The Radar: Bio-Rad Laboratories (BIO)

Trade-Ideas LLC identified Bio-Rad Laboratories (BIO) as a strong and under the radar candidate

Strong And Under The Radar Today: Bio-Rad Laboratories (BIO)

Strong And Under The Radar Today: Bio-Rad Laboratories (BIO)

Trade-Ideas LLC identified Bio-Rad Laboratories (BIO) as a strong and under the radar candidate

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: APAM, ATAI, BIO, BIO.B, DFRG, ESE, SGA, SLGN, SNI, UA, WLH Downgrades: EGP, HMHC, HWKN, MMI, MORE, PMBC Initiations: CPHR, DEA, SHAK, TTOO Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BCR, DCUB, DVD, KLAC, QLGC Downgrades: ABG, AKAM, ATTU, BIO, BMY, BOKF, CHH, FFIV, HMC, HUBB, LLL, LRN, MJN, MLI, OSIS, RGEN, SCS, SP, TRN, URI, VLY, WERN, ZION Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Bio-Rad And Illumina To Co-Develop Comprehensive Solution For Single-Cell Genomics

Bio-Rad And Illumina To Co-Develop Comprehensive Solution For Single-Cell Genomics

Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIOb) and Illumina, Inc.

Strong And Under The Radar Today: Bio-Rad Laboratories (BIO)

Strong And Under The Radar Today: Bio-Rad Laboratories (BIO)

Trade-Ideas LLC identified Bio-Rad Laboratories (BIO) as a strong and under the radar candidate

Strong And Under The Radar: Bio-Rad Laboratories (BIO)

Strong And Under The Radar: Bio-Rad Laboratories (BIO)

Trade-Ideas LLC identified Bio-Rad Laboratories (BIO) as a strong and under the radar candidate

Bio-Rad Laboratories (BIO) Showing Signs Of Being Strong And Under The Radar

Bio-Rad Laboratories (BIO) Showing Signs Of Being Strong And Under The Radar

Trade-Ideas LLC identified Bio-Rad Laboratories (BIO) as a strong and under the radar candidate

Bio-Rad Laboratories Moves Up In Market Cap Rank, Passing Fossil Group

Bio-Rad Laboratories Moves Up In Market Cap Rank, Passing Fossil Group

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Bio-Rad Laboratories, Inc. was identified as having a larger market cap than the smaller end of the S&P 500, for example Fossil Group Inc , according to The Online Investor.

New Lifetime High Reached By Bio-Rad Laboratories (BIO)

New Lifetime High Reached By Bio-Rad Laboratories (BIO)

Trade-Ideas LLC identified Bio-Rad Laboratories (BIO) as a new lifetime high candidate

Bio-Rad Laboratories (BIO) Showing Signs Of Being Strong And Under The Radar

Bio-Rad Laboratories (BIO) Showing Signs Of Being Strong And Under The Radar

Trade-Ideas LLC identified Bio-Rad Laboratories (BIO) as a strong and under the radar candidate

TheStreet Quant Rating: A- (Buy)